# Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis

> **NCT00782613** · PHASE2 · TERMINATED · sponsor: **Synvista Therapeutics, Inc** · enrollment: 30 (estimated)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** 4,4-dimethyl-benziso-2H-selenazine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00782613
- **Lead sponsor:** Synvista Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Study has been termination early due to financial contraints.
- **Last updated:** 2009-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00782613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00782613, "Efficacy and Safety of Topical ALT-2074 (SYI-2074) for Treatment of Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00782613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*